Oncology Brothers: Practice-Changing Cancer Discussions

Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in HER2-targeted therapies for upper gastrointestinal malignancies, with Drs. Shruti Patel and Samuel Cytryn.
 
Join us as we discussed:
The recent approval of zanidatamab and its implications for HER2-positive esophageal and gastric adenocarcinoma
The role of trastuzumab in treatment and its associated side effects, including cardiotoxicity and infusion reactions
Addressing different dose used for trastuzumab deruxtecan (T-DXd) in upper GI space, along with important side effect profile to keep in mind
The importance of shared decision-making in treatment options and the impact of dosing strategies on patient outcomes
 
We also covered the critical need for biomarker-driven treatment approaches, including HER2 status and PD-L1 scores, and how these factors influence therapy choices.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
 ⁠X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Tune in for an informative discussion that bridges the gap between research and clinical practice, ensuring that patients receive the best care possible. Don't forget to like, subscribe, and hit the notification bell for more episodes!
#HER2positive, #UpperGICancer, #Zanidatamab, #Trastuzumab, #TDXd, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Samuel Klempner, a GI medical oncologist from the Massachusetts General Hospital, to discuss the evolving treatment landscape for upper gastrointestinal cancers, specifically esophageal, gastroesophageal junction (GEJ), and gastric adenocarcinoma.
 
During our discussion we touched on:
The treatment algorithm for localized disease, including the shift from local therapy to a combination of systemic and local treatments
The current standard of care, which includes perioperative durvalumab with the FLOT regimen and surgery
The role of chemoradiation therapy for patients who are not surgical candidates and the nuances of managing residual disease
The importance of biomarker-driven treatment in metastatic disease, focusing on HER2 status, PD-L1 scores, and CLDN18.2 expression
The latest advancement, the approval of zanidatamab and clinical implications for treatment strategies
Management of side effects associated with these therapies and the importance of patient quality of life
 
Whether you're a healthcare professional or someone interested in the latest in cancer care, this episode provides valuable insights into the complexities of treating upper GI cancers.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!
#UpperGICancer, #GastricCancer, #Zanidatamab, #Zolbetuximab, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we welcomed Dr. Jonathan Friedberg, a leading lymphoma expert, to discuss modern treatment approaches for follicular lymphoma and mantle cell lymphoma.
 
Join us as we explored:
The diagnostic workup for follicular lymphoma, including the role of bone marrow biopsy and staging imaging
Treatment strategies for early-stage and symptomatic follicular lymphoma, including rituximab, obinutuzumab, and chemotherapy-based approaches
The evolving role of maintenance therapy and what recent studies have shown about progression-free and overall survival
New treatment options in relapsed/refractory follicular lymphoma, including tafasitamab and epcoritamab
The importance of TP53 testing in mantle cell lymphoma and the evolving role of BTK inhibitors in frontline treatment
The role of CAR T-cell therapy and bispecific antibodies in the evolving lymphoma treatment landscape
 
This discussion provided practical insights into current treatment algorithms and emerging strategies for patients with follicular lymphoma and mantle cell lymphoma.
 
Whether you're a hematologist, oncologist, advanced practice provider, nurse, pharmacist, trainee, or healthcare professional interested in lymphoma care, this episode offers an expert perspective on the rapidly evolving treatment landscape.
 
If you found this discussion valuable, please like the video, subscribe to the Oncology Brothers, and share your thoughts in the comments.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Subscribe for more expert discussions on hematology, oncology, lymphoma, immunotherapy, cellular therapy, targeted therapy, and advances in cancer care.
#FollicularLymphoma #MantleCellLymphoma #Lymphoma #Hematology #OncologyBrothers

In this episode of the Oncology Brothers podcast we had a chance to discuss the current treatment landscape for diffuse large B-cell lymphoma (DLBCL) with Dr. Mazyar Shadman, from the Fred Hutch Cancer Center.
 
We dived deep into frontline treatment options, including R-CHOP and polatuzumab-based regimens, and explored how to effectively risk stratify patients using the International Prognostic Index (IPI) score and the Hans algorithm. Dr. Shadman shared insights on the use of CAR T-cell therapy in both early and late relapsed settings, discussing the differences between axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and the importance of bridging and holding therapies.
 
Key topics covered in this episode:
Frontline treatment options for DLBCL
The role of polatuzumab in early-stage disease
Treatment paradigms for advanced-stage DLBCL
CAR T-cell therapy: who should receive it and when
The importance of community and tertiary care partnerships in improving patient access to innovative therapies
 
Join us for an informative discussion that highlights the evolving landscape of DLBCL treatment and the critical role of collaboration in oncology care.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and share your thoughts in the comments!
#DLBCL, #CARTtherapy, #RCHOP, #Polatuzumab, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dove deep into the groundbreaking advancements in pancreatic cancer treatment, focusing on the recent approval of daraxonrasib.
 
Join us as we welcome Mark Goldsmith, MD, PhD, CEO of Revolution Medicines, who shared his inspiring journey from clinical practice to the biotech industry. Discover the challenges and triumphs behind bringing this first-in-class drug to market, and learn about the significant impact it has on patient outcomes.
 
Keypoints:
Daraxonrasib is a first-in-class RAS inhibitor approved for the treatment of pancreatic cancer, targeting a mutation present in over 90% of cases.
The drug's development represents a major shift in pancreatic cancer, moving from a historically untreatable disease to a promising target for precision medicine.
Early clinical trial results demonstrated remarkable tumor shrinkage, driving urgency to bring the therapy to patients.
Management of side effects, including rash and gastrointestinal issues, is essential for optimal patient outcomes.
Ensuring patient access—despite high treatment costs—remains a priority, with patient assistance programs and insurance navigation support in place.
Future directions include combination therapies and the goal of transforming pancreatic cancer into a manageable chronic disease.
 
We discussed the critical gaps between academic research and community practice, the importance of understanding side effects, and the financial implications of new therapies. Dr. Goldsmith also highlighted the future of pancreatic cancer treatment and the ongoing commitment to improving patient care.
 
Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights and information.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in cancer treatment and research!
#PancreaticCancer, #Daraxonrasib, #RASinhibitor, #DrugDevelopment, #OncologyBrothers

Welcome to another episode of the Oncology Brothers! In this episode, we dived into the recent FDA approval of camizestrant for the treatment of hormone receptor–positive metastatic breast cancer, based on the SERENA-6 trial.
We welcomed Dr. Erica Mayer, a breast medical oncologist from the Dana-Farber Cancer Institute, who shared her insights on the trial's design, findings, and the significance of detecting ESR1 mutations before clinical progression. We discussed the implications of this approval, including the shift in treatment strategies, the importance of ctDNA monitoring, and the potential benefits for patient quality of life.
Key topics covered in this episode:
Overview of the SERENA-6 trial and its findings
The role of ESR1 mutations in treatment resistance
The efficacy and safety profile of camizestrant
Practical insights on integrating next-generation sequencing (NGS) testing into clinical practice
Management of side effects, including bradycardia and QT prolongation
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
#Camizestrant, #SERENA6, #ESR1mutation, #BreastCancer, #OncologyBrothers
 

Welcome to the Oncology Brothers podcast! In this episode, we talked about the most recent developments in the world of myeloproliferative neoplasms (MPNs), including the exciting FDA approvals of ropeginterferon alfa-2b for essential thrombocythemia (ET) and rusfertide for polycythemia vera (PV).
 
The leading author Dr. John Mascarenhas, an MPN specialist from the Mount Sinai, New York, shared insights from the SURPASS-ET study, which paved the way for the official approval of ropeginterferon alfa-2b in ET. Dr. Mascarenhas discussed the study design, findings, and the implications of using ropeginterferon alfa-2b compared to traditional therapies like anagrelide and hydroxyurea.
 
Key topics covered in this episode included:
Overview of the SURPASS-ET study and its significance
Efficacy and tolerability of ropeginterferon alfa-2b in ET
Side effect profiles of ropeginterferon alfa-2b vs anagrelide
The importance of monitoring JAK2 allele burden and its clinical relevance
Considerations for using ropeginterferon alfa-2b in frontline therapy for select patients
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Join us as we explore the evolving landscape of MPN treatment and the potential for disease modification with ropeginterferon alfa-2b. Don't forget to like, subscribe, and check out our other discussions on oncology topics!
#EssentialThrombocythemia, #MPN, #Ropeginterferon, #SURPASSET, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute.
 
Join us as we explored:
The critical distinction between primary and secondary myelofibrosis and its implications for treatment
The essential workup needed before initiating therapy, including bone marrow biopsy and mutation analysis
Anemia management strategies, including the use of erythropoiesis-stimulating agents and the innovative drug luspatercept
The role of JAK inhibitors in treatment, including ruxolitinib, momelotinib, pacritinib, and fedratinib, and how to choose among them based on patient needs
The importance of spleen reduction and its correlation with patient outcomes and survival
Insights into the side effect profiles of various treatments and the future of myelofibrosis management
 
Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on navigating the complexities of myelofibrosis treatment.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
•⁠  ⁠X/Twitter: https://x.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ 
Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! 
#Myelofibrosis, #JAKinhibitors, #Hematology, #MPN, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET).
 
We dived deep into the side effect profiles and management strategies for key treatments, including:
Hydroxyurea: Learnt about dosing strategies, monitoring, and the importance of managing acute and chronic side effects such as leg ulcers and skin cancer risks
Ropeginterferon alfa-2b: Discover the benefits and potential side effects, including flu-like symptoms and neuropsychiatric issues, and how to approach dosing for patients with pre-existing conditions
Ruxolitinib: Understand the common side effects, including myelosuppression and weight gain, and the critical importance of tapering off the medication rather than stopping abruptly
Rusfertide: Get insights into this new hepcidin mimetic and its promising role in managing PV, along with potential side effects to monitor
 
Join us for a comprehensive tox check discussion that aims to equip healthcare professionals with clinical pearls for managing these treatments effectively.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:
X/Twitter: ⁠https://x.com/oncbrothers⁠ 
⁠Instagram: ⁠https://www.instagram.com/oncbrothers⁠ 
Website: ⁠https://oncbrothers.com/⁠ 
 
Subscribe for more insights and updates from the Oncology Brothers!
#PolycythemiaVera, #MPN, #EssentialThrombocythemia, #CytotoxicTherapies, #OncologyBrothers
 

Welcome to the Oncology Brothers podcast! In this episode, we dived into the recent approval of rusfertide for polycythemia vera, based on the findings from the VERIFY study. We were joined by Dr. Andrew Kuykendall, an MPN specialist from the Moffitt Cancer Center, who shared insights on the drug's mechanism of action as a hepcidin mimetic and its clinical implications.
 
Key topics discussed included:
The unique challenges of managing polycythemia vera, with balancing of erythrocytosis and iron deficiency
The design and findings of the VERIFY study, highlighting the significant reduction in the need for phlebotomy among patients treated with rusfertide
The potential for individualized patient care and the integration of rusfertide with existing cytoreductive therapies
Insights into dosing, side effects, and the drug's impact on patient quality of life
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Join us as we explore how rusfertide can change the treatment landscape for polycythemia vera and improve patient outcomes. Don't forget to like, subscribe, and hit the notification bell for more episodes!
#Rusfertide, #PolycythemiaVera, #VERIFYstudy, #MPN, #Hematology